Kiniksa_COVID-002: Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia |
|
|
| Recruiting | 2 | 6 | Italy | mavrilimumab (KPL-301) - Kiniksa | Kiniksa Pharmaceuticals Ltd. | Coronavirus, Severe COVID-19 Pneumonia | | | | |
NCT04492514: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation |
|
|
| Recruiting | 2 | 60 | US | Mavrilimumab, KPL-301, Placebo, Control | Kristin Hudock, Kiniksa Pharmaceuticals, Ltd. | COVID 19, SARS-CoV 2, Pneumonia | 05/21 | 05/21 | | |